Morgan Stanley’s Iterum Therapeutics ITRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-15,713
| Closed | -$471 | – | 8502 |
|
|
2026
Q1 | $471 | Buy |
15,713
+10,000
| +175% | +$2.51K | ﹤0.01% | 7627 |
|
|
2025
Q4 | $1.91K | Sell |
5,713
-2,900
| -34% | -$1.56K | ﹤0.01% | 7251 |
|
|
2025
Q3 | $5.77K | Sell |
8,613
-760
| -8% | -$595 | ﹤0.01% | 7054 |
|
|
2025
Q2 | $9.33K | Buy |
9,373
+2,900
| +45% | +$3.02K | ﹤0.01% | 6872 |
|
|
2025
Q1 | $7.96K | Sell |
6,473
-5,256
| -45% | -$7.8K | ﹤0.01% | 6871 |
|
|
2024
Q4 | $20.8K | Buy |
11,729
+6,250
| +114% | +$9.8K | ﹤0.01% | 6562 |
|
|
2024
Q3 | $5.97K | Hold |
5,479
| – | – | ﹤0.01% | 6857 |
|
|
2024
Q2 | $6.27K | Hold |
5,479
| – | – | ﹤0.01% | 6797 |
|
|
2024
Q1 | $8.44K | Hold |
5,479
| – | – | ﹤0.01% | 6761 |
|
|
2023
Q4 | $10.8K | Sell |
5,479
-8,471
| -61% | -$10.5K | ﹤0.01% | 6635 |
|
|
2023
Q3 | $11.2K | Hold |
13,950
| – | – | ﹤0.01% | 6695 |
|
|
2023
Q2 | $14.9K | Hold |
13,950
| – | – | ﹤0.01% | 6662 |
|
|
2023
Q1 | $13.9K | Buy |
13,950
+5,460
| +64% | +$6.29K | ﹤0.01% | 6755 |
|
|
2022
Q4 | $7.13K | Sell |
8,490
-1,157
| -12% | -$1.65K | ﹤0.01% | 7050 |
|
|
2022
Q3 | $16K | Sell |
9,647
-5,100
| -35% | -$15.5K | ﹤0.01% | 6887 |
|
|
2022
Q2 | $44K | Sell |
14,747
-335
| -2% | -$1.25K | ﹤0.01% | 6671 |
|
|
2022
Q1 | $81K | Buy |
15,082
+2,101
| +16% | +$12.1K | ﹤0.01% | 6453 |
|
|
2021
Q4 | $76K | Sell |
12,981
-17,446
| -57% | -$135K | ﹤0.01% | 6593 |
|
|
2021
Q3 | $255K | Buy |
30,427
+26,625
| +700% | +$328K | ﹤0.01% | 5871 |
|
|
2021
Q2 | $131K | Sell |
3,802
-1,164
| -23% | -$25.2K | ﹤0.01% | 6222 |
|
|
2021
Q1 | $105K | Buy |
4,966
+3,885
| +359% | +$92.5K | ﹤0.01% | 5980 |
|
|
2020
Q4 | $16K | Buy |
+1,081
| New | +$12.7K | ﹤0.01% | 6500 |
|
|
2020
Q3 | – | Sell |
-6
| Closed | – | – | 6782 |
|
|
2020
Q2 | $0 | Sell |
6
-318
| -98% | -$12.6K | ﹤0.01% | 6659 |
|
|
2020
Q1 | $13K | Buy |
324
+200
| +161% | +$8.41K | ﹤0.01% | 5955 |
|
|
2019
Q4 | $8K | Buy |
124
+123
| +12,300% | +$6K | ﹤0.01% | 6314 |
|
|
2019
Q3 | $0 | Sell |
1
-1
| -50% | -$97 | ﹤0.01% | 6690 |
|
|
2019
Q2 | $0 | Sell |
2
-49
| -96% | -$5.45K | ﹤0.01% | 6690 |
|
|
2019
Q1 | $6K | Sell |
51
-67
| -57% | -$6.14K | ﹤0.01% | 6292 |
|
|
2018
Q4 | $9K | Sell |
118
-55
| -32% | -$5.21K | ﹤0.01% | 6186 |
|
|
2018
Q3 | $17K | Buy |
173
+113
| +188% | +$14.8K | ﹤0.01% | 6184 |
|
|
2018
Q2 | $10K | Buy |
+60
| New | +$10.8K | ﹤0.01% | 6307 |
|
Other funds holding ITRM
Morgan Stanley's ITRM Position: Q2 2026 in Review
Morgan Stanley sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 15,713 shares — an estimated $471 sold.
Morgan Stanley first reported a position in ITRM in Q2 2018 and held it in 31 quarters. The position peaked at $255K in Q3 2021. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.
- Morgan Stanley reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 15,713 Iterum Therapeutics shares in Q2 2026, an estimated $471.
- Morgan Stanley first reported a position in Iterum Therapeutics in Q2 2018 and held it in 31 quarters.
- Morgan Stanley's Iterum Therapeutics position peaked at $255K in Q3 2021.
- 2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.